Drug Profile
Anti-CD4 monoclonal antibody YTS 177-9
Latest Information Update: 26 Aug 2002
Price :
$50
*
At a glance
- Originator Nonindustrial source
- Class Antineoplastics; Antirheumatics; Antivirals; Monoclonal antibodies
- Mechanism of Action CD4 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Diabetes mellitus; Transplant rejection